# Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC

> **NCT04275713** · PHASE2 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 41 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Metformin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04275713
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-22
- **Primary completion:** 2024-06-11
- **Final completion:** 2024-11-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04275713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04275713, "Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04275713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*